The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.

The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.
PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…
Richard L. Allman, MD, MS, FACP, FACR |
The patient, a 76-year-old woman, had very active polyarticular rheumatoid arthritis (RA), despite triple therapy with conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), low-dose corticosteroids and occasional intra-articular injections—the latter providing only transient symptomatic relief. She had elevated inflammatory markers and a 28-joint Disease Activity Score (DAS-28) score of 7.4. Because of the severity of her…
Matthew J. Mandell, DO, Yishui Chen, MD, Prerna Rastogi, MD, PhD, & Rebecca Tuetken, MD, PhD |
Syphilis, an ancient disease caused by the spirochete Treponema pallidum, has been historically referred to as the great mimicker given its heterogenous presentation. Both systemic lupus erythematosus (SLE) and syphilis can have multi-systemic involvement. Both parvovirus B19 and syphilis have been reported to cause histologic features similar to those seen in lupus nephritis. We present…
Rochelle Castillo, MD, MS, Andro Licaros, MD, & Jemima Albayda, MD |
In medicine, as in advertising, pictures can be worth a thousand words. From arthritis to vasculitis, imaging studies have been variably employed to aid in the diagnosis, treatment, risk stratification and prognostication of patients with rheumatic and musculoskeletal disorders. The same holds true with the idiopathic inflammatory myopathies (IIM), in which the clinical utility is…
Patrice Fusillo |
During ACR Convergence 2022 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…
Mia Taylor Chandler, MD, MPH |
“I tell everyone who comes into her room now, ‘You will not disrespect my daughter again. No one will,’” recounts Sarah’s mother. “Every time a [provider] acts rude to her, Sarah tells me, ‘Ma, I’m used to it now,’ and I have to insist ‘No! Baby, you should never get used to that.’ … Dr….
In a post hoc analysis of two clinical trials, Maassen et al. demonstrated that 40% of patients with early RA or undifferentiated arthritis experienced disease flare after primary glucocorticoid discontinuation despite background treatment with conventional synthetic DMARDs.
From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…
Using data from cohorts with detailed lifestyle data and lengthy follow-up, Hahn et al. demonstrated that healthy lifestyle behaviors are associated with a lower risk of developing rheumatoid arthritis (RA), concluding that a substantial proportion of RA may be preventable.